Muna Kubvumbi 2019, HopeMed yakapinda muchibvumirano chepasirese cherezinesi neBayer AG pamusoro pekusimudzira uye kushambadzira kwemunhu monoclonal antibody yakanangana nePRL receptor yekurapa kwevarume nevakadzi pateni bvudzi kurasikirwa, endometriosis, uye zvimwe zvirwere zvisingaperi zvine dysregulated prolactin. (PRL) chiratidzo. Antibody iyi yakaratidza hunhu hwakanaka mumhando dzemhuka dzinosanganisira modhi dzeNHP uye kudzidza nezvekuchengetedzwa kwevanhu. Kurapa kwayo kwezviratidzo zviviri zvikuru, endometriosis uye androgenetic alopecia, ese akatenderwa neUS FDA yeChikamu II chekiriniki miedzo. The Phase II kliniki yekuedza yeHMI-115 mu endometriosis yakatotangisa kunyoresa varwere muUS mukupera kwa2021. Yayo Phase II yekiriniki yekuyedza kurapwa kwe androgenetic alopecia inzvimbo yepasirese yakawanda-center, randomized, double-blind, placebo- inodzorwa kudzidza, iyo yakarongwa kuti iitwe muUnited States, Australia nedzimwe nyika.
Dr. Henri Doods, Mutungamiriri Mukuru weHopeMed, akati "Ndinodada zvikuru kuti FDA yakabvumirawo yechipiri IND yedu iyo inokosha inokosha kukambani yedu yechidiki. Idanho rakakosha rakananga kuchinangwa chedu kuunza Chekutanga-mu-Kirasi uye yakasiyaniswa zvakanyanya zvigadzirwa kuvarwere. Ose ari maviri endometriosis uye alopecia zviratidzo apo varwere vakamirira nechido nzira itsva dzekurapa nekuvandudzwa kwesimba uye kuchengeteka. Kubudirira kwekuva nemvumo mbiri dzeIND munguva pfupi yakadaro ikurudziro yeboka rose. Takazvipira zvakanyanya kuenderera mberi nekusimbisa nekuwedzera zviitiko zvedu zveR&D kuunza nzira itsva dzekurapa kuvarwere pasi rose. "